



Vacc-iNTS 2021 Annual Meeting

26th – 27th October 2021

Agenda

Day 1: 26th October 2021

OPENING SESSION

Chair: Donata Medaglini (SVA, UNISI)

9:30 Welcome and Introduction - *Donata Medaglini (SVA, UNISI)*

9:35 The Vacc-iNTS project: overview and progress - *Donata Medaglini (SVA, UNISI)*

Session I: SERO-EPIDEMIOLOGY STUDIES

Chair: Melita Gordon (UOL)

9:45 Sero-epidemiology studies: Malawi field site (WP7) –
Melita Gordon, Helen Dale and Esmelda Chirwa (UOL/UMLW)

10:05 Sero-epidemiology studies: Kenya field site (WP7) –
Sam Kariuki and Mercy Ngetich (KEMRI)

10:25 Sero-epidemiology studies: Burkina Faso field site (WP7) –
Soura Bassiahi A. and Lady Nana (UO)

10:45 Sero-epidemiology studies: Ghana field site (WP7) –
Ellis Owusu-Dabo and Agyapong O. Francis (KNUST)

11:05-11:20 General discussion – Q&A

11:20-11:25 Vacc-iNTS 2021 Annual Meeting Group photo

Session II: PLANNING AND EVALUATION OF iNTS VACCINE DEPLOYMENT IN AFRICA

Chairs: John Crump (OTAGO) and Florian Marks (UCAM/IVI)

11:25 Systematic Reviews on iNTS disease (WP8) – *Christian Marchello (OTAGO)*

11:40 Mathematical modelling of iNTS disease (WP8)
Jong-Hoon Kim (UCAM/IVI) and Gianluca Breggi (SVA/FAS)

11:55 iNTS and Neglected Tropical Diseases/Febrile illness classification (WP8)
Gianluca Breggi (SVA/FAS)

12:05 Champion the uptake of iNTS vaccine in resource-poor settings of Africa (WP9)
Stefano Malvolti (MMGH)

12:15 Cost-of-Illness and Cost-Effectiveness analyses for the introduction of an iNTS vaccine in
Sub-Saharan Africa (WP9) – *Vittal Mogasale (UCAM, IVI)*

12:30-12:45 General discussion

12:45 – 12:50 Conclusion of day 1

12:50 – 13:20 Scientific Advisory Board Meeting (*reserved only to SAB members*)



Day 2: 27th October 2021

Session III: CLINICAL TRIAL

Chairs: Francesco Berlanda Scorza and Audino Podda (GVGH)

- 9:30 Vaccine manufacturing and stability assessment of vaccine lots (WP1-2)
Rocio Canals Alvarez (GVGH)
- 9:45 Phase I (stage I) clinical study in Europe (WP3) (WP6) – *Brama Hanumunthadu (UOXF)*
- 9:55 Phase I (stage II) clinical study in Africa (WP4) – *Esther Muthumbi (KEMRI-WT)*
- 10:05-10:20 General discussion

Session IV: IMMUNE RESPONSE ANALYSIS

Chair: Andrew Pollard (UOXF)

- 10:20 Serological analysis of Vacc-iNTS clinical trial samples (WP5) – *Omar Rossi (GVGH)*
- 10:30 Computational analysis of multiparametric flow cytometry data (WP6) –
Annalisa Ciabattini (UNISI)
- 10:40-10:55 General discussion

Session V: TRAINING, MANAGEMENT, DISSEMINATION AND IMPACT ASSESSMENT

Chair: Donata Medaglini (UNISI, SVA)

- 10:55 Training activities in endemic countries (WP10) – *Omar Rossi (GVGH)*
- 11:05 Management, Dissemination and Impact Assessment (WP11-18) -
Tiziana Spadafina (SVA)

Session VI: CONCLUSION OF THE MEETING

- 11:15 - 11:35 General Assembly
Scientific Advisory Board Meeting (*reserved only to SAB members*)
Ethics Advisory Board Meeting (*reserved only to EAB members*)
- 11:35 – 11:55 Feedback from Scientific and Ethics Advisory Boards – *Chair: Allan Saul*
- 11:55 – 12:00 Concluding remarks and next steps -
Rino Rappuoli (SVA, GSK) and Donata Medaglini (SVA, UNISI)
- 12:00 – 13:00 Steering Committee Meeting (*reserved only to SC members*)

Vacc-iNTS 2021 Annual Meeting

26th and 27th October 2021 09:30 AM (CEST)

Join via Zoom:

<https://zoom.us/j/95948778545?pwd=aFJPRm5DVIN2YzFNT2owOTludWNNdzog>

Meeting ID: 959 4877 8545

Password: iNTS





Vacc-iNTS 2021 Annual Meeting

26th – 27th October 2021

List of Participants

Name	Affiliation	Country
Agyapong Opoku Francis	Kwame Nkrumah University of Science and Technology	GH
Ashton Philip	University of Liverpool	UK
Bak Jeong Eun	University of Cambridge	UK
Bassiahi Soura Abdramane	University of Ouagadougou	BF
Berlanda Scorza Francesco	GSK Vaccines Institute for Global Health	IT
Binka Fred	University of Health and Allied Sciences	GH
Breghi Gianluca	Fondazione Achille Sclavo/Sclavo Vaccines Association	IT
Cakpo Enoch	University of Ouagadougou	BF
Canals Alvarez Rocio	GSK Vaccines Institute for Global Health	IT
Chafuwa Hlulose	University of Malawi	MW
Chiliengi Roma	Centre for Infectious Disease Research in Zambia	ZM
Chirwa Esmelda	University of Malawi	MW
Ciabattini Annalisa	University of Siena	IT
Cochard Landry	GSK	BE
Colucci Anna Maria	GSK Vaccines Institute for Global Health	IT
Crump John	University of Otago	NZ
Dale Helen	University of Liverpool	UK
Dasmané Dielbogo	University of Ouagadougou	BF
Fiorino Fabio	University of Siena	IT
Gordon Melita	University of Liverpool/University of Malawi	UK/MW
Hamaluba Mainga	KEMRI-Wellcome Trust Research Programme	KE
Han Ji Hyun	International Vaccine Institute	KR
Hanumunthadu Brama	University of Oxford	UK
Haselbeck Andrea	International Vaccine Institute	KR

Holst Johan	Norwegian Institute of Public Health	NO
Jacobs Jan	Institute of Tropical Medicine	BE
Kambiya Paul	University of Malawi	MW
Kariuki Sam	Kenya Medical Research Institute	KE
Kaslow David	PATH	USA
Kim Deok Ryun	International Vaccine Institute	KR
Kim Jong-Hoon	International Vaccine Institute	KR
Kumar Arora Ashwani	GSK Vaccines	IT
Lucchesi Simone	University of Siena	IT
Malvolti Stefano	MMGH Consulting GmbH	CH
Mantel Carsten	MMGH Consulting GmbH	CH
Marchello Christian	University of Otago	NZ
Marks Florian	University of Cambridge/ International Vaccine Institute	UK/KR
Medaglini Donata	University of Siena/Sclavo Vaccines Association	IT
Misiri Theresa	Malawi Liverpool Wellcome Trust	MW
Mogasale Vittal	International Vaccine Institute	KR
Mukasa David	International Vaccine Institute	KR
Murphy Victoria	University of Oxford	UK
Muthumbi Esther	KEMRI-Wellcome Trust Research Programme	KE
Mwakiseghile Felistas	University of Malawi	MW
Necchi Francesca	GSK Vaccines Institute for Global Health	IT
Ngetich Mercy	Kenya Medical Research Institute	KE
Nyirenda Tonney	University of Malawi	MW
Onsare Robert	Kenya Medical Research Institute	KE
Ouédraogo Moussa	University of Ouagadougou	BF
Owino Nelly	University of Oxford	UK
Owusu Michael	Kwame Nkrumah University of Science and Technology	GH
Owusu-Dabo Ellis	Kwame Nkrumah University of Science and Technology	GH
Pak Gi-Deok	International Vaccine Institute	KR
Pastore Gabiria	University of Siena	IT
Patel Priyanka	University of Malawi	MW
Pettini Elena	University of Siena	IT
Podda Audino	GSK Vaccines Institute for Global Health	IT
Pollard Andrew	University of Oxford	UK
Polvere Jacopo	University of Siena	IT
Pozzi Gianni	University of Siena	IT
Ramasamy Maheshi	University of Oxford	UK

Rappuoli Rino	GSK Vaccines/Sclavo Vaccines Association	IT
Rashid Vincent	Malawi Liverpool Wellcome Trust	MW
Rossi Omar	GSK Vaccines Institute for Global Health	IT
Santoro Francesco	University of Siena	IT
Saul Allan	Burnet Institute	AU
Scott Anthony	KEMRI-Wellcome Trust Research Programme	KE
Siribie Mohamadou	International Vaccine Institute	BF
Smith Peter	London School of Hygiene and Tropical Medicine	UK
Spadafina Tiziana	Sclavo Vaccines Association	IT
Tack Bieke	Institute of Tropical Medicine	BE
Toffalini Federica	GSK Vaccines	IT
Twumasi-Ankrah Sampson	Kwame Nkrumah University of Science and Technology	GH
Van Rensburg Craig	International Vaccine Institute	KR
Wandji Nana Lady	University of Ouagadougou	BF
Zellweger Raphael	International Vaccine Institute	KR

This project has received funding from the European Union's Horizon 2020
Research and Innovation Programme under grant agreement No 815439

